China Chinese Patent Medicine Industry Report, 2010
  • Dec/2010
  • Hard Copy
  • USD $1,500
  • Pages:63
  • Single User License
    (PDF Unprintable)       
  • USD $1,400
  • Code: ZYM018
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,100
  • Hard Copy + Single User License
  • USD $1,700
      
China is the birthplace of Chinese Patent Medicine, and a major producer and consumer of Chinese patent medicine in the world. Driven by both policy incentives and market demand, Chinese patent medicine has developed well in China. From 2006 to 2009, China’s industrial output value and sales revenue of Chinese patent medicine grew at annual rates of 13.9% and 12.7% respectively. The terminal sales revenue of Chinese patent medicine has always accounted for about 30% of the total pharmaceutical revenue of China since 2006. As of August 2010, there had been 1,522 Chinese patent medicine manufacturers in China, including over 30 listed companies, such as Tasly, Tongrentang and Yunnan Baiyao; there had been over 10,000 kinds of Chinese patent medicine, such as Tasly’s Compound Danshen Dripping Pill (Fu Fang Dan Shen Di Wan), Tongrentang’s Bolus of Six Drugs Including Rehmannia (Liu Wei Di Huang Wan) and Bolus of Black-bone Chicken (Wu Ji Bai Feng Wan); there had been over 40 dosage forms, such as traditional bolus, ointment, powder and pellet as well as modern capsule, tablet and spray.

Industrial Output Value and Prime Operating Income of Chinese Patent Medicine in China, 2006-2009(RMB bn)
 2010122005.gif
Source: ResearchInChina; National Bureau of Statistics of China

As China’s Chinese patent medicine has gained increasing international recognition and high profit (generally, the operating profit margin is above 70%), and the chemical and pharmaceutical industry has encountered development bottlenecks, global pharmaceutical giants and related institutions have marched into China’s Chinese patent medicine-related fields through joint venture, sole proprietorship or other forms. For example, Novartis and Kunming Pharmaceutical signed a General Agreement on Patent Development Permit for the R & D and production of artemether raw materials, U.S. National Institutes of Health (NIH) (the world's largest medical research institute and research fund management institution) and Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited signed a cooperative agreement on the research of anti-virus mechanism of Baiyunshan Radix Isatidis Granule.

Due to the particularity of Chinese patent medicine market, manufacturers generally can only set foot in some market segments instead of all application fields of Chinese patent medicine. Moreover, as there are a lot of manufacturers engaged in Chinese patent medicine, the competition among them is intense, and the market concentration is low even in market segments. For example, in the field of Chinese patent medicine for cardiovascular and cerebrovascular diseases, top 4 brands accounted for 12.4%, 14.6% and 17.1% of the total market respectively during 2007 to 2009, while top 10 brands held 24.1%, 27.8% and 31.2% of the total market respectively during 2007 to 2009. However, the market concentration of Chinese patent medicine for cardiovascular and cerebrovascular diseases is showing an upward trend in China.

The report analyzes the domestic & global operating environment, current development, supply & demand, competition pattern, import & export and market segments of China’s Chinese patent medicine industry. It also studies the operation and development prospect of 10 listed Chinese patent medicine enterprises, including Tasly, Kanion Pharmaceutical, Yunnan Baiyao, Tibet Cheezheng Tibetan Medicine, Tibet Rhodiola Pharmaceutical, Kunming Pharmaceutical, CONBA, Tongrentang and Guilin Sanjin.
1. Overview of Chinese Patent Medicine
1.1 Definition and Classification
1.2 Comparison among Chinese Patent Medicine, Herbal Medicine and Natural Medicine
1.3 Industry Chain

2. Market Operating Environment for China’s Chinese Patent Medicine
2.1 Global Environment
2.1.1 Polices
2.1.2 Market Status
2.1.3 Development Trend
2.2 Domestic Environment
2.2.1 Polices
2.2.2 Operation of TCM Industry

3. Overview of China’s Chinese Patent Medicine Market
3.1 Status Quo
3.2 Supply and Demand
3.2.1 Supply
3.2.2 Demand
3.3 Competition
3.4 Import & Export
3.4.1 Export
3.4.2 Import
3.5 Development Prospect and Trend
3.5.1 International Market
3.5.2 Domestic Market
3.5.3 Influence of Raw Materials

4. Chinese Patent Medicine Market Segments in China
4.1 Cardiovascular and Cerebrovascular
4.1.1 Market Scale
4.2 Anti-tumor
4.3 Respiratory System

5. Major Chinese Patent Medicine Manufacturers in China
5.1 Tasly
5.1.1 Profile
5.1.2 Operation
5.1.3 Development Prospect and Trend
5.2 Kanion Pharmaceutical
5.2.1 Profile
5.2.2 Operation
5.2.3 Development Prospect and Advantages
5.3 Yunnan Baiyao
5.3.1 Profile
5.3.2 Operation
5.3.3 Development Prospect and Advantages
5.4 Pien Tze Huang
5.4.1 Profile
5.4.2 Operation
5.4.3 Development Prospect and Advantages
5.5 Tibet Cheezheng Tibetan Medicine
5.5.1 Profile
5.5.2 Operation
5.5.3 Development Prospect and Advantages
5.6 Tibet Rhodiola Pharmaceutical
5.6.1 Profile
5.6.2 Operation
5.6.3 Development Prospect and Advantages
5.7 Kunming Pharmaceutical
5.7.1 Profile
5.7.2 Operation
5.7.3 Development Prospect and Advantages
5.8 CONBA
5.8.1 Profile
5.8.2 Operation
5.8.3 Development Prospect and Advantages
5.9 Tongrentang
5.9.1 Profile
5.9.2 Operation
5.9.3 Development Prospect and Advantages
5.10 Guilin Sanjin
5.10.1 Profile
5.10.2 Operation
5.10.3 Development Prospect and Advantages
Chinese Patent Medicine Industry Chain
Distribution of global Herbal Medicine Market, 1999-2005
Market Shares of Herbal Medicine Enterprises in the World, 2005
Cases of Foreign Enterprises Entering the Field of Chinese Herbal Medicine  
National Policies Related with Chinese Patent Medicine
Total Output Value of Traditional Chinese Medicine Industry and by Sub-sector, 2006-2009
Industrial Output Value and Sales Revenue of Chinese Patent Medicine in China, 2006-2009
Number of Chinese Patent Medicine Enterprises in China, 2006-Aug. 2010
Chinese Patent Medicines Included in the Catalog of Essential Medicines and National Medical Insurance-covered Medicines of China by Category, 2009
Output and Growth Rate of Chinese Patent Medicine in China, 2006-2009
Output of Chinese Patent Medicine (by Region) in China, 2009
Chinese Patent Medicine Terminal Sales Revenue and Its Proportion in Pharmaceutical Market in China, 2005-2009
Product Structure of Chinese Patent Medicine Market (by Purpose and Effectiveness) in China, 2009
China’s Export Volume and Value of Chinese Patent Medicine, 2006-H1 2010        
Export Destinations of China’s Chinese Patent Medicine, H1 2010
China’s Export Volume and Value of Chinese Patent Medicine by Product, H1 2010        
Top 10 Provinces by Export of Chinese Patent Medicine, H1 2010
China’s Import Volume and Value of Chinese Patent Medicine, 2007-H1 2010      
Countries and Regions Where China Imported Chinese Patent Medicine from, H1 2010
Major Regions Where China Imported Chinese Patent Medicine from, H1 2010
Gross Margin of Major Chinese Patent Medicine Enterprises in China, 2007-H1 2010
Monthly Prices of Several Chinese Herbal Medicines in China, 2010
Top 10 Brands of Chinese Patent Medicine for Cardio-cerebral-vascular Diseases in China, 2007-2009
Proportion of Chemical Pharmaceutical to Chinese Patent Medicine in Chinese Anti-tumor Market, 2009
Top 10 Brands of Chinese Patent Medicine for Anti-tumor and Immune Regulation in China, 2009
Market Scale and Growth Rate of Chinese Patent Medicine (Granule) for Throat and Heat Expelling in China, 2006-2009
Top 10 Brands of Chinese Patent Medicine for Throat in China, 2008
Top 10 Brands of Chinese Patent Medicine (Granule) for Heat Expelling in China, 2008
Operating Income and Total Profit of Tasly, 2007-H1 2010
Operating Income of Tasly (by Industry), H1 2010
Operating Income of Tasly (by Region), H1 2010
Modern Traditional Chinese Medicine Industry Chain of Tasly
Operating Income and Total Profit of Kanion Pharmaceutical, 2007-H1 2010
Operating Income and Operating Profit Margin of Kanion Pharmaceutical (by Industry or Product), 2009-H1 2010
Operating Income and Total Profit of Yunnan Baiyao, 2007-H1 2010
Operating Income and Operating Profit Margin of Yunnan Baiyao (by Industry or Product), 2009-H1 2010
Operating Income of Yunnan Baiyao (by Region), 2009-H1 2010
Operating Income and Total Profit of Pien Tze Huang, 2007-H1 2010
Operating Income and Operating Profit Margin of Pien Tze Huang by Product, 2007-H1 2010
Operating Income of Pien Tze Huang (by Region), 2009-H1 2010
Operating Income and Total Profit of Tibet Cheezheng Tibetan Medicine, 2007-H1 2010
Operating Income and Operating Profit Margin of Tibet Cheezheng Tibetan Medicine (by Product), 2007-H1 2010
Operating Income of Tibet Cheezheng Tibetan Medicine (by Region), 2009-H1 2010
Operating Income and Total Profit of Tibet Rhodiola Pharmaceutical, 2007-H1 2010
Operating Income and Operating Profit Margin of Tibet Rhodiola Pharmaceutical (by Product), 2009-H1 2010
Operating Income and Total Profit of Kunming Pharmaceutical, 2007-H1 2010
Operating Income and Operating Profit Margin of Natural Medicine of Kunming Pharmaceutical, 2007-H1 2010
Operating Income of Kunming Pharmaceutical (by Region), 2009-H1 2010
Operating Income and Total Profit of CONBA, 2007-H1 2010
Operating Income and Operating Profit Margin of CONBA's Modern Herbal Medicine, 2007-H1 2010
Operating Income of CONBA (by Region), 2009-H1 2010
Operating Income and Total Profit of Tongrentang, 2007-H1 2010
Operating Income and Net Profit of Subsidiaries of Tongrentang, 2009
Operating Income of Tongrentang (by Region), 2009-2010
Operating Income and Total Profit of Guilin Sanjin, 2007-H1 2010
Operating Income and Operating Profit Margin of Guilin Sanjin (by Product), 2009-H1 2010
Operating Income of Guilin Sanjin (by Region), 2009-H1 2010

China Blood Product Industry Report, 2020-2027

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which h...

China Medical Robot Industry Report, 2020-2026

Medical robot is the most promising segment of service robot market. By one estimate, globally 7,200 units of medical robots were sold and valued at $2.58 billion in 2019, compared with 5,100 units (u...

China In Vitro Diagnostic (IVD) Industry Report, 2019-2025

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China’s IV...

China Aged Care Industry Report, 2019-2025

China’s society has aged before it gets rich. By the end of 2018, people aged over 60 had numbered 249.5 million in the country, or 17.9% of the total population, of which those aged over 65 were 167 ...

China Dental Industry Report, 2019-2025

Nowadays, the Chinese people have a growing awareness of oral health and healthy behaviors. 60.1% of residents have knowledge about oral health; 24.1% of 5-year-old children and 31.9% of 12-year-old c...

China Hospital Industry Report,2019-2025

The people’s growing awareness of health care and the acceleration of population aging have brought prosperity to China’s hospital industry. As of February 2019, there had been a total of 33,000 hospi...

China Dental Industry Report, 2017-2021

As living standards continue to improve and the awareness of oral health grows, consumers’ demand for dental services has kept increasing and the dental industry in China has witnessed robust developm...

China Interferon Industry Report, 2016-2021

Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple sclerosis, condyloma acuminatum and other diseases. Wherein, IFN-α is mainly suitable for curing hepatitis B and hepat...

China Hospital Industry Report,2016-2020

In recent years, "Opinions on Promoting the Development of Health Service Industry" and other related policies, the people’s growing awareness of health care and the acceleration of population aging h...

China Aged Care Industry Report, 2016-2020

China entered the aging society early in 1999. By the end of 2015, China’s population aged over 60 reached 222 million and the old-age dependency ratio 13.9%. By 2020, China’s population aged over 60 ...

China Medical Robotics Industry Report, 2016-2020

Medical robotics can be used in surgery, rescue, transport, care, rehabilitation, dispensing and so on for the sick and wounded. Especially, surgical, rehabilitation and dispensing robots are the R &a...

China Dental Industry Report, 2016-2020

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental apparatus (equipments and consumables), dental medical services, etc. With ...

China Medical Imaging Diagnosis Industry Report, 2015-2019

Against the background of a surge in social demand, handsome profit and the favorable opportunity brought by health care reform, the medical imaging industry, especially medical imaging equipment indu...

China Heparin Industry Report, 2015-2018

As the world's largest heparin API producer and exporter, China seizes about 80% share of the global heparin API market. After the explosive growth in 2008-2010, the stagnant international market and ...

Global and China Stem Cell Industry Report, 2015-2018

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hund...

China Hospital Industry Report, 2015-2018

Stimulated by the demand, the number of hospitals in China rose from 21,979 in 2011 to 26,479 at the end of May 2015, an increase of 4,500 in total. Among them, public hospitals showed an overall decl...

China Independent Clinical Laboratory Industry Report, 2015-2018

The independent clinical laboratory originated from the U.S. and is relatively mature in developed countries/regions like North America, Europe, and Japan, whose independent clinical laboratory market...

China Medical Robot Industry Report, 2014-2018

Medical robots can be applied to surgeries, rescue, transport, nursing and rehabilitation of the sick and wounded. Wherein, surgery and rehabilitation robots are two striking market segments. Due to ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号